A late-night bidding war for a Californian biotech company has taken the value of healthcare deals in the past 15 months to nearly half a trillion dollars in a fresh sign that sky-high valuations have not slowed the pace of pharmaceuticals dealmaking.
对美国加州一家生物科技公司的深夜竞标战，使过去15个月的医药业并购交易总值逼近5000亿美元，这一最新迹象表明，天价估值并未放缓制药业撮合交易的步伐。
您已阅读7%（326字），剩余93%（4157字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。